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Abstract: During exercise, non-invasive ventilation (NIV) prolongs endurance in chronic obstructive
pulmonary disease (COPD), but routine use is impractical. The VitaBreath device provides portable
NIV (pNIV); however, it can only be used during recovery. We assessed the effect of pNIV compared
to pursed lip breathing (PLB) on exercise tolerance. Twenty-four COPD patients were randomised
to a high-intensity (HI: 2-min at 80% peak work rate (WRpeak) alternated with 2-min recovery;
n = 13), or a moderate-intensity (MOD: 6-min at 60% WRpeak alternated with 2-min recovery; n = 11)
protocol, and within these groups two tests were performed using pNIV and PLB during recovery in
balanced order. Upon completion, patients were provided with pNIV; use over 12 weeks was assessed.
Compared to PLB, pNIV increased exercise tolerance (HI: by 5.2 ± 6.0 min; MOD: by 5.8 ± 6.7 min)
(p < 0.05). With pNIV, mean inspiratory capacity increased and breathlessness decreased by clinically
meaningful margins during recovery compared to the end of exercise (HI: by 140 ± 110 mL and
1.2 ± 1.7; MOD: by 170 ± 80 mL and 1.0 ± 0.7). At 12 weeks, patients reported that pNIV reduced
anxiety (median: 7.5/10 versus 4/10, p = 0.001) and recovery time from breathlessness (17/24 patients;
p = 0.002); 23/24 used the device at least weekly. pNIV increased exercise tolerance by reducing
dynamic hyperinflation and breathlessness in COPD patients.
Keywords: non-invasive ventilation; COPD; exercise tolerance; pulmonary rehabilitation
1. Introduction
Exercise training is the cornerstone of Pulmonary Rehabilitation (PR) inducing clinically
meaningful improvements in exercise tolerance in patients with chronic obstructive pulmonary disease
(COPD) [1]. Dynamic hyperinflation (DH) during exercise limits the normal increase in tidal volume,
worsening breathlessness and reducing exercise capacity [2]. Additionally, DH and the concomitant
high mean intrathoracic pressure swings are associated with adverse effects on central hemodynamic
regulation, reducing the supply of oxygenated blood to deconditioned peripheral muscles [3,4].
This contributes to leg discomfort and further limits exercise tolerance. Different ergogenic strategies
have been successfully employed to reduce exercise-induced breathlessness and leg discomfort,
including oxygen and heliox supplementation, non-invasive ventilation (NIV) and various intermittent
exercise modalities [5–8]. Oxygen supplementation is commonly used during exercise in order to
reduce desaturation and breathlessness [9]. Heliox supplementation is beneficial but impractical
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and expensive; therefore, it has primarily been used for research purposes [10]. Standard NIV is
infrequently used due to the application of bulky equipment and the need for close supervision during
exercise training [11].
The VitaBreath (Philips, Respironics, Morrisville, PA, USA) is a portable, handheld,
battery-powered, non-invasive ventilation device (pNIV) intended to reduce activity-related shortness
of breath [12]. It delivers 18 cm H2O inspiratory and 8 cm H2O expiratory pressures, but can only be
used during recovery periods interspersing bouts of physical activity. The purpose of this study was to
test the effect of pNIV compared to pursed lip breathing (PLB) on exercise tolerance comprising two
different intermittent modalities, namely moderate-intensity (6 min at 60% peak work rate (WRpeak))
and high-intensity (2 min at 80% WRpeak) exercise. As both modalities are recommended by the
British Thoracic Society and joint American Thoracic Society/European Respiratory Society guidelines
for PR [13,14], we wished to explore whether pNIV support was equally effective during exercise
comprising different intensity and duration characteristics.
We hypothesised that the use of pNIV compared to PLB would increase exercise tolerance by
reducing the intensity of breathlessness during bouts of moderate- or high-intensity intermittent
exercise and would confer greater benefit if used more frequently with the high-intensity protocol.
Besides the physiological implications of pNIV during controlled laboratory exercise conditions,
we were interested in the effects of pNIV on anxiety, breathlessness, symptom burden and ability
to perform daily life physical tasks. Accordingly, we assessed the frequency and ease of use of the
VitaBreath device alongside symptom burden, as well as attitudes toward the device over 12 weeks
following the completion of the exercise protocols.
2. Experimental Section
2.1. Study Population
Twenty-four patients with stable COPD who met the following criteria participated in the study:
(1) male or female aged 40 years or older, (2) current or previous smoking history: 10 or more pack
years, (3) spirometry confirmed stable COPD (GOLD stages II–IV) under optimal medical therapy
and (4) substantial exercise-induced DH (i.e.,: change in inspiratory capacity from baseline >0.15 L or
>4.5% of predicted resting inspiratory capacity (IC)) [2]. Exclusion criteria (Appendix A) included
COPD exacerbation within 6 weeks, unstable comorbidities, inability to exercise and intolerance of
the device. The investigations were carried out following the rules of the Declaration of Helsinki of
1975 [15], revised in 2013. NHS Research Ethics Committee approval (REC: 17/NE/0085) and Clinical
Trials registration (NCT03068026) were obtained. Data were collected at the Respiratory Department,
North Tyneside General Hospital. All participants provided written consent.
2.2. Study Design
This was a randomised, open-label cross-over trial comparing the use of pNIV to PLB during
recovery periods in two different intermittent exercise regimes (Figure 1). Patients underwent a ramp
incremental cardiopulmonary exercise test (CPET) to determine WRpeak, and then were randomly
assigned to a high-intensity (HI) or a moderate-intensity (MOD) protocol. Within these groups,
each patient performed two more visits using both pNIV and PLB during recovery from exercise in
balanced order (see below); the primary outcome was exercise endurance time (TLim). Patients were
on optimal bronchodilator therapy including daily LAMA and LABA and no changes to medication
were made during the trial. Tests were performed without supplemental oxygen. Following the last
visit, all 24 ‘patients were given a VitaBreath device to use it as they wished and were contacted at
2 and 12 weeks to assess their use of, and attitudes towards, the device. Patients received advice on the
use of the device for symptomatic relief after exertion, but the frequency of use was not prescribed.
The full details of study methods are shown in Appendix A.
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Figure 1. Consort diagram. Following  the  initial  ramp  incremental  cardiopulmonary exercise  test 
(CPET) to determine WRpeak, 24 patients were randomly allocated either to a high‐intensity (HI) or 
a moderate‐intensity (MOD) exercise protocol. Within these two protocols (HI or MOD), each patient 
performed two more exercise tests using both portable non‐invasive ventilation (pNIV) and pursed 
lip  breathing  (PLB) during  recovery  from  exercise  in  balanced  order,  alternating which  test was 
performed first. 
2.3. Assessments 
Prior to the first exercise, test patients performed baseline screening comprising: (1) Spirometry, 
lung volume measurements and diffusion capacity (DLCO), (2) a resting electrocardiograph (ECG) 
and (3) medical history and physical examination by a clinician. In addition, they were familiarised 
with  both  high‐  and moderate‐intensity  exercise  protocols.  They  practiced  using  the VitaBreath 
device  and  the  correct  adoption  of PLB with  guidance  from  a physiotherapist  over  6–8 practice 
exercise sessions. 
All CPET were performed on an electromagnetically braked cycle ergometer  (Ergoselect 200, 
ergoline GmbH, Bitz, Germany) with the patients maintaining a pedalling frequency of 50–60 rpm. 
Pulmonary gas exchange and ventilatory variables were recorded breath‐by‐breath via a portable gas 
exchange analyser  (K4b2, Cosmed, Shepperton, UK)  throughout  the  test. The modified Borg Scale 
was used  to  rate  the magnitude of breathlessness  and  leg discomfort  at  the  end of  the  test  [16]. 
Inspiratory capacity (IC) manoeuvres were performed at rest, every 2 min during cycling and at peak 
exercise, in order to evaluate the rate of dynamic hyperinflation (DH) [2]. Full details of CPET are 
shown in Appendix A. 
i r . s rt i r . Following the initial r i cr t l c r i l ary rcis t st
( ) t eter i e e , tie ts ere r l ll c te eit er t i -i te sit ( I) r
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perfor ed t o ore exercise tests using both portable non-invasive ventilation (p I ) and pursed
lip breathing (PLB) during recovery fro exercise in balanced order, alternating hich test as
perfor ed first.
2.3. Assessments
Prior to the first exercise, test patients performed baseline screening comprising: (1) Spirometry,
lung volume measurements and diffusion capacity (DLCO), (2) a resting electrocardiograph (ECG) and
(3) medical history and physical examination by a clinician. In addition, they were familiarised with
both high- and moderate-intensity exercise protocols. They practiced using the VitaBreath device and
the correct adoption of PLB with guidance from a physiotherapist over 6–8 practice exercise sessions.
All CPET were performed on an electromagnetically braked cycle ergometer (Ergoselect 200,
ergoline GmbH, Bitz, Germany) with the patients maintaining a pedalling frequency of 50–60 rpm.
Pulmonary gas exchange and ventilatory variables were recorded breath-by-breath via a portable
gas exchange analyser (K4b2, Cosmed, Shepperton, UK) throughout the test. The modified Borg
Scale was used to rate the magnitude of breathlessness and leg discomfort at the end of the test [16].
Inspiratory capacity (IC) manoeuvres were performed at rest, every 2 min during cycling and at peak
exercise, in order to evaluate the rate of dynamic hyperinflation (DH) [2]. Full details of CPET are
shown in Appendix A.
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2.4. Interventions
Patients randomised to moderate- or high-intensity intermittent exercise (Figure 1) underwent
two tests within the allocated exercise protocol using either pNIV or PLB during recovery periods
in a balanced order sequence (Figure 2). The order of the recovery method was determined by an
alternating sequence, ensuring balance across the group. Throughout the test, pulmonary gas exchange
variables were recorded breath-by-breath (K4b2, Cosmed, Shepperton, UK). Percentage arterial oxygen
saturation (SpO2) was measured by a pulse oximeter every minute.
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Figure 2. Exercise protocols: (a) High‐intensity 2‐min intermittent exercise protocol and (b) moderate‐
intensity 6‐min intermittent exercise protocol. Within these two protocols (HI or MOD), each patient 
performed  two more  visits/exercise  tests  using  pNIV  and  PLB  during  recovery  from  exercise  in 
balanced order. Typical examples of high‐ and moderate‐intensity exercise bouts are shown by open 
squares and recovery periods by shadowed squares. 
The  high‐intensity  intermittent  exercise  protocol  (sustained  at  80%  WRpeak)  consisted  of 
repetitive 2‐min exercise bouts, separated by 2‐min recovery periods to the limit of tolerance. This 
was defined as the point at which the patient signalled the inability to continue exercising or could 
not maintain the required pedalling rate (i.e., 50–60 revolutions/min) despite being encouraged by 
the investigators. IC manoeuvres were performed on the 2nd minute of each exercise bout. During 
the 1st min of each recovery period, participants used either pNIV (VitaBreath device) or PLB. During 
the 2nd min of each recovery period, participants performed an IC manoeuvre to assess the magnitude 
of DH and scored the intensity of their breathlessness and leg discomfort using the Borg scale (Figure 
2a). SpO2 measurements were performed on the 2nd minute of each exercise bout following each IC 
manoeuvre. 
The moderate‐intensity intermittent exercise protocol (sustained at 60% WRpeak) consisted of 
repetitive  6‐min  exercise bouts,  separated by  2‐min  recovery periods  to  the  limit of  tolerance  as 
described above. Use of pNIV or PLB, and assessments were performed as above. IC manoeuvres, 
followed by SpO2 measurements, were performed on the 2nd, 4th and 6th minute of each exercise 
bout and on  the 2nd minute of each  recovery period  following  completion of each exercise bout 
(Figure 2b). 
Cardiac Output (CO), Heart Rate (HR) and Stroke Volume (SV) were recorded continuously at 
rest, during exercise and in recovery by the Physio Flow device (Enduro, PF‐07, Manatec Biomedical, 
Folschviller, France), whereas  systemic oxygen delivery  (DO2) was  estimated  from CO and SpO2 
(Appendix A) [17–21]. 
Following completion of the three visits, all patients were provided with a VitaBreath device to 
use at home as they wished. Use of, and perceived benefit from, the VitaBreath device was examined 
at 2 and 12 weeks following the completion of the exercise testing protocols. The survey included 
questions on symptom burden, ability to perform daily tasks and perceived benefit from the device 
(Table S1 online supplement). 
Figure 2. Exercise protocols: (a) High-intensity 2-min intermittent exercise protocol and
(b) moderat -int nsity 6-min intermittent exercise protocol. Within these two protocols (HI or
MOD), each pat ent perform d two more visits/exercise tests using pNIV and PLB during recovery
from exercise in balanced ord r. Typical examples of high- and mo erate-intensity exercise bout are
shown by pen squares and recovery periods by shadowed squares.
The high-intensity intermittent exercise protocol (sustained at 80% WRpeak) consisted of repetitive
2-min exerc se bouts, separated by 2-min re overy peri ds to the limit of tolerance. This was defined
as the point at which the patient signalled the inability to continue exercising or could not mai tain t e
required p lling rate (i.e., 50–60 revolu io s/min) despite being encouraged by the nvestigators.
IC manoeuvres were pe formed on the 2nd minute of each exercise bout. During the 1st min of each
recovery period, participants used either NIV (VitaBreat device) or PLB. During the 2nd min of each
recovery period, participants rf rmed an IC manoeuvre to assess the magnitude of DH and scored the
int nsity of their breathlessness and leg discomfort using th Borg scale (Fig re 2a). SpO2 measurements
were performed on the 2nd minute of each exercise bout follow ng each IC manoeuvre.
The moderat -intensity intermittent exercise protocol (sustained at 60% WRpeak) co sisted of
repetitive 6-min exercise bouts, separated by 2-min recovery periods to the limit of tolerance as
described above. Use of pNIV or PLB, and asse smen s were performed as above. IC ma oeuvres,
followed by SpO2 m asuremen w re performed on the 2nd, 4th and 6th minute of each exercise bout
and on the 2nd minut each recovery period followi g completion of each exercis bout (Figure 2b).
Car iac Output (CO), Heart Rat (HR) and Stroke Volume (SV) were recorded continuously at
rest, during exercise and recovery by the Physio Fl w device (Enduro, PF-07, Manatec Biom dical,
Folschviller, France), whereas systemic oxygen delivery (DO2) was estimated from CO and SpO2
(Appendix A) [17–21].
Following completion of the three visits, all patients were provided with a VitaBr ath device to
use at home as they wished. Use of, and perceived ben fit from, the VitaBreath evice was examined
at 2 and 12 weeks following the completion of the exercise testing protocols. The survey included
questions on symptom burden, ability to perform daily tasks and perc ived benefit from the device
(Table S1 online supplement).
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2.5. Statistics
Verification of sample size within each exercise modality was based on the study by Bianchi and
colleagues [22] comparing pressure support ventilation (PSV) to control breathing during exercise.
Using the mean difference in endurance time (3.4 min) between PSV and control breathing, and standard
deviation (SD) (4.6 min), an alpha significance level of 0.05 (2-sided) and 90% power, a minimum total
sample size of 10 patients was calculated to be sufficient to detect significant differences in endurance
time between pNIV and PLB trials within each exercise modality (Appendix A). Randomisation was
performed by independent staff within our institution and stratified by WRpeak (<50 or ≥50 watts)
and FEV1 (<50 or ≥50% predicted) using a block size of 4. The study team was blinded to the
randomisation sequence.
Data are presented as mean ± SD unless otherwise stated. One-way ANOVA was employed
to detect differences in exercise tolerance (minutes) between moderate- and high-intensity exercise
modalities and between pNIV and PLB breathing modalities. For each individual patient, the duration
of exercise to the limit of tolerance when using the PLB technique was divided into four percentiles
(i.e., 25%, 50%, 75% and 100%) of total endurance time including the recovery phases. A two-way
ANOVA with repeated measurements followed by appropriate post hoc analysis was employed
to compare changes at iso-time across these four percentiles between the PLB and pNIV trials for:
IC, CO, DO2, breathlessness and leg discomfort. For IC we calculated the change between recovery
periods and the end of exercise bouts. When analysing the questionnaire results, data are presented as
median (IQR) or absolute number (%). The Wilcoxon signed-rank test was used for comparing 2- and
12-week interval scale (Likert style) data and McNemar’s test for nominal response data. The level of
significance for all analyses was set at p < 0.05.
3. Results
3.1. Study Population
Patients randomised (between June 2017 and July 2018) to exercise modalities were matched
in terms of demographic and clinical characteristics exhibiting severe airflow limitation and lung
hyperinflation at rest without resting hypoxemia (Table 1). Baseline peak exercise capacity was severely
impaired; patients exhibited profound exercise-induced DH and moderate arterial oxygen desaturation
at the limit of tolerance during the CPET (Table 2). Five (20.8%) of the patients were current smokers,
with 14 (58.3%) having been admitted to hospital for an exacerbation of COPD (ECOPD) in the past
12 months. The median number of ECOPD (hospital or community managed) in the past 12 months
was 2 (1–4.75). The median extended MRC dyspnoea score (eMRCD) was 4 (3–4) [23,24].
Table 1. Patient demographic characteristics at baseline.
Variable High-Intensity (n = 13) Moderate-Intensity (n = 11) p-Value
Gender (M/F) 5/8 5/6
Age (years) 66 ± 7 68 ± 10 0.510
BMI 26.9 ± 6.9 25.6 ± 6.8 0.659
FEV1 (% predicted) 46 ± 15 46 ± 21 0.948
FVC (% predicted) 87 ± 18 91 ± 21 0.605
FEV1/FVC (%) 43 ± 14 37 ± 12 0.487
IC (litres) 1.96 ± 0.56 2.03 ± 0.78 0.810
IC (% predicted) 79 ± 22 78 ± 23 0.807
TLC (% predicted) 130 ± 29 131 ± 15 0.975
FRC (% predicted) 172 ± 49 175 ± 37 0.845
DLCO (% predicted) 38 ± 18 38 ± 20 0.980
BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity;
IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual capacity; DLCO, transfer factor
of the lung for carbon monoxide; M, male; F, female; values are mean ± standard deviation (SD).
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Table 2. Peak physiological variables at the limit of tolerance during cardiopulmonary exercise test (CPET).
Variable High-Intensity (n = 13) Moderate-Intensity (n = 11) p-Value
WR (Watts) 48 ± 25 48 ± 26 0.977
WR (% predicted) 46 ± 19 45 ± 26 0.883
VO2 (mL/kg/min) 13.5 ± 3.9 13.4 ± 3.2 0.808
VO2 (% predicted) 60 ± 12 61 ± 21 0.911
VE/MVV (%) 1.00 ± 0.21 0.99 ± 0.26 0.787
∆IC from rest (litres) 0.60 ± 0.38 0.47 ± 0.33 0.399
SpO2 (%) 92 ± 5 92 ± 3 0.827
CO (L/min) 10.5 ± 3.9 11.2 ± 2.7 0.635
HR (beats/min) 113 ± 15 110 ± 18 0.728
SV (mL) 94 ± 30 101 ± 19 0.513
Dyspnoea (Borg 1–10) 4.2 ± 1.2 3.8 ± 0.7 0.269
Leg discomfort (Borg 1–10) 3.8 ± 1.1 3.3 ± 1.6 0.442
WR, work rate; VO2, oxygen uptake; VE, minute ventilation; MVV, Maximum voluntary ventilation; ∆IC, change from
rest in inspiratory capacity; SpO2, arterial oxygen saturation; CO, cardiac output; HR, heart rate; SV, stroke volume;
Values are mean ± SD.
3.2. Endurance Time
Compared to PLB, pNIV increased exercise endurance time during for both intermittent exercise
modalities (HI-pNIV: from 26.2 ± 6.9 to 31.4 ± 8.3 min (p = 0.008); MOD-pNIV: from 30.3 ± 11.3 to
36.1 ± 11.0 min (p = 0.016)) without differences in the magnitude of improvement between the two
exercise modalities (p = 0.244) (Figure 3).
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Figure 3. Exercise endurance time using pNIV (solid bars) and PLB (grey bars) during high- and
moderate-intensity exercise protocols (a). Effect of pNIV on individual patient exercise endurance time
during high-intensity (b) and moderate-intensity (c) exercise protocols. Solid lines indicate mean values.
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Figure 3. Exercise endurance  time using pNIV  (solid bars) and PLB  (grey bars) during high‐ and 
moderate‐intensity exercise protocols  (a). Effect of pNIV on  individual patient exercise endurance 
time during high‐intensity (b) and moderate‐intensity (c) exercise protocols. Solid lines indicate mean 
values. 
3.3. Other Outcomes 
The mean increase in IC during recovery periods compared to the end of exercise exceeded the 
clinically meaningful margin  (i.e., >4.5% of predicted  resting  IC: 110–119 mL)  [2,7] when patients 
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3.3. Other Outcomes
The mean increase in IC during recovery periods compared to the end of exercise exceeded the
clinically meaningful margin (i.e., >4.5% of predicted resting IC: 110–119 mL) [2,7] when patients used
pNIV for both HI-pNIV: 140 ± 110 mL and MOD-pNIV: 170 ± 80 mL exercise modalities (Figure 4a,c).
The mean change in IC in recovery compared to the end of exercise with PLB did not reach a clinically
meaningful m rg neither for HI-PLB: 10 ± 290 mL nor for MOD-PLB: 100 ± 140 mL exercise
modalities (Figure 4a,c).
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Figure 4. Effect of the application of pNIV (closed ircl s) compared to PLB (open circles) on inspiratory
capac ty calculated as the change between recov ry p riods and th en of high-intensity intermitten
(a) or od rate-intensity (b) and moderate-intensity (c) exercise bouts and sympt ms of breathlessness
during recovery from high-intensity (d) exercise. Responses are shown for both PLB and pNIV at
iso-time across the four percentiles (25%, 50%, 75% and 100%) of the total endurance time when using
the PLB technique. Data are presented as mean ± standard error of the mean (SEM).
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Compared to PLB at Tlim, the change in IC from rest was not different (p = 0.379) between the
two intermittent exercise modalities with the use of pNIV (Table 3).
Table 3. Metabolic and respiratory responses at the limit of tolerance of high- and moderate-intensity exercise.
High-Intensity Moderate-Intensity
Variable PLB pNIV Support p-Value PLB pNIVSupport p-Value
Work Rate (watts) 38 ± 20 38 ± 20 - 30 ± 17 30 ± 17 -
∆IC (litres) −0.37 ± 0.31 −0.37 ± 0.28 0.964 −0.29 ± 0.25 −0.27 ± 0,24 0.819
Dyspnoea (Borg) 4.8 ± 1.2 3.9 ± 1.4 0.005 4.0 ± 1.1 3.3 ± 1.1 0.004
Leg Discomfort (Borg) 4.5 ± 1.5 4.1 ± 1.8 0.027 4.1 ± 1.2 3.3 ± 1.6 0.011
VO2 (mL/min/kg) 11.89 ± 3.20 11.95 ± 3.45 0.879 12.82 ± 3.27 12.72 ± 3.11 0.778
VE (litres/min) 34.75 ± 18.43 36.47 ± 18.12 0.206 34.57 ± 14.64 33.84 ± 14.25 0.444
VT (litres) 1.2 ± 0.5 1.2 ± 0.5 0.202 1.2 ± 0.5 1.2 ± 0.5 0.549
RF (breaths/min) 29 ± 5 30 ± 5 0.256 30 ± 5 29 ± 3 0.409
CO (litres/min) 9.9 ± 2.6 10.5 ± 2.7 0.070 10.3 ± 2.4 10.5 ± 2.3 0.193
HR (beats/min) 105 ± 13 108 ± 15 0.172 114 ± 19 114 ± 16 0.725
SV (mL/beat) 94 ± 23 96 ± 22 0.487 90 ± 16 91 ± 13 0.485
SBP (mmHg) 146 ± 23 158 ± 23 0.002 142 ± 29 148 ± 22 0.285
DBP (mmHg) 82 ± 8 89 ± 9 0.024 78 ± 18 84 ± 17 0.049
a-VO2 (mL/100 mL) 8.9 ± 2.9 8.3 ± 3.1 0.205 8.9 ± 2.9 8.6 ± 2.9 0.371
SpO2 (%) 92 ± 5 93 ± 4 0.104 94 ± 3 93 ± 3 0.148
∆IC: change from baseline in inspiratory capacity, VO2: oxygen uptake, VE: minute ventilation, VT: tidal volume,
RF: breathing frequency, CO: cardiac output, HR: heart rate, SV: stroke volume, SBP: systolic blood pressure,
DBP: diastolic blood pressure, a-VO2: whole body arteriovenous oxygen difference content, SpO2: arterial oxygen
saturation. pNIV: portable Non-Invasive Ventilation, PLB: Pursed lip breathing technique. Values are mean ± SD.
Compared to PLB across different fractions of total endurance, time application of pNIV was
associated with a clinically meaningful reduction [7,25] in breathlessness during HI-pNIV (by: 1.2 ± 1.7,
p = 0.022) and MOD-pMIV (by: 1.0 ± 0.7, p = 0.002) exercise modalities (Figure 4b,d). There were no
significant differences (p = 0.518) in breathlessness scores between the two modalities with pNIV.
Compared to PLB across different fractions of total endurance time, the application of pNIV
was associated with lower leg discomfort during HI-pNIV (by: 0.5 ± 0.8, p = 0.050) and MOD-pNIV
(by: 0.8 ± 1.1 (p = 0.031)) exercise modalities (Figure 5c,f). There were no differences (p = 0.268) in leg
discomfort scores between the two modalities with pNIV.
In comparison to PLB, across different fractions of total endurance time, CO and DO2 were
greater with pNIV during both HI-pNIV (by 0.3 ± 1.1 L/min (p = 0.035) and by 70 ± 40 mL/min
(p = 0.040), respectively) and MOD-pNIV (by 0.8 ± 0.9 L/min (p = 0.045) and 160 ± 40 mL/min (p = 0.040),
respectively) exercise modalities (Figure 5). There were no differences (p = 0.519 and 0.463, respectively)
in these variables between the two exercise modalities with pNIV (Figure 5).
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3.4. Use and Perceived Benefits of the VitaBreath Device
Compared to the pre-VitaBreath period, at 12 weeks, patients were significantly less anxious
about becoming breathless on a 10-point Likert Scale: median (IQR) pre-VitaBreath = 7.5 (5.25–8.75);
12 weeks = 4.0 (2–5.75); (p = 0.001) and 17 of 24 patients perceived a shorter time to recovery from
breathlessness (p = 0.002) (Table 4).
Comparing responses at 2 and 12 weeks, there was no attrition in the frequency of use of the device
(p = 0.590); at 12 weeks, 23/24 patients continued to use the device at least weekly, and at 16 weeks, daily.
Patients found improvement in the speed, duration and confidence with which they could undertake
activities of daily living, with no loss of these effects at 12 weeks (Table S1, online supplement).
Frequency of breathlessness (p = 0.670), planning around breathlessness (p = 0.220), and needing to
stop activities due to breathlessness (p = 0.500) did not change between 2 and 12 weeks. Whilst all
patients describe the VitaBreath as easy to use (good or better), most describe its portability as poor
(8/24) or fair (7/24). Patients described being more active with VitaBreath than without (2 weeks 13/23;
12 weeks 14/24 patients; p = 0.940) (Table S1, online supplement). Between 2 and 12 weeks, there was
a non-significant increase in use of VitaBreath for outdoor activities (15/24 vs. 19/23 patients; p = 0.130).
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At 12 weeks, the median (IQR) likelihood that patients would recommend VitaBreath to others = 10
(7–10), but to purchase at the actual cost in sterling pounds = 3 (1–5) on a 10-point likert scale (Table S1,
online supplement).
Table 4. Effects of the use of VitaBreath device on anxiety, symptom burden and ability to perform tasks.
Question Pre-VitaBreath Post-VitaBreath p-Value
How anxious are you about becoming
short of breath (SOB)?
1 = Not at all anxious
10 = Very anxious
7.50 (5.25–8.75) 4.00 (2–5.75)
0.001 *
20
improvements
2 worse
2 ties
How long did it take you to recover
from SOB?
0.002 *
17
improvements
3 worse
4 ties
<1 min 0 (0%) 6 (25%)
2–3 min 7 (29.2%) 9 (37.5%)
4–5 min 3 (12.5%) 4 (16.7%)
5–7 min 5 (20.8%) 1 (4.2%)
7–10 min 5 (20.8%) 2 (8.3%)
More than 10 min 4 (16.7%) 2 (8.3%)
Data presented as median (IQR) or absolute number (%); * Wilcoxon signed-rank test.
4. Discussion
The major finding of the study is that the use of pNIV during recovery periods interspersing
moderate- and high-intensity bouts of intermittent exercise significantly improved exercise tolerance
compared to PLB. This is probably due to more rapid recovery from exercise-induced dynamic
hyperinflation, with associated improvements in cardiac output and systemic oxygen delivery.
The physiological responses shown were matched by a reduction in breathlessness and leg discomfort
in recovery from exercise. Patients reported that the VitaBreath device improved anxiety around
breathlessness, as well as perceived time of recovery from it during activities of daily living.
NIV has previously been used during exercise training in patients with severe COPD to lessen
breathlessness and increase exercise capacity [11,26]. A Cochrane analysis of studies using NIV during
exercise training provides conflicting and moderate quality evidence of beneficial effects on exercise
capacity and the role of this intervention remains unclear [27–31]. The main drawbacks of NIV in these
studies were the difficulty in using the equipment during pulmonary rehabilitation and cost, including
the time required to supervise patients during training [29]. Nevertheless, recent meta-analyses
conclude that there is a need for further randomised clinical trials [29,32].
The VitaBreath device is designed to overcome the problems associated with the use of traditional
NIV and is primarily intended to aid recovery from breathlessness after activities in daily life. It is
light, handheld and battery operated. This, and future pNIV devices, may offer benefits within PR,
particularly in intermittent/interval training regimes. One technical limitation of the VitaBreath device
is that the expiratory and inspiratory positive airway pressures (EPAP and IPAP, respectively) are fixed.
Excessive EPAP can worsen hyperinflation and circulatory compromise. In our study population,
the majority of patients showed no worsening of DH or circulatory compromise whilst using pNIV
during recovery periods. However, in six patients (three per group) the improvement in DH was
greater with PLB than pNIV, thereby suggesting that the fixed pressures were sub-optimal in at least
some of our cohort. Accordingly, in future devices the ability to adjust EPAP and pressure support is
desirable and could potentially be automated.
Recently, a non-invasive “open” ventilation (NIOV) system operating in conjunction with
a portable oxygen tank was found to decrease respiratory muscle activation and dyspnoea and to
improve cycle ergometer exercise tolerance [33]. We have shown that the use of pNIV (VitaBreath)
during intermittent exercise is associated with longer exercise endurance time (by 19–20%), with less
DH and breathlessness. Continuous positive pressure support throughout exercise is much less
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practical in daily life, but confers greater improvement in exercise tolerance, including the use of:
continuous positive airway pressure (26–40%) [22,34], proportional assist ventilation (23–43%) [17,22,34],
pressure support ventilation (by 32–38%) [22,35], inspiratory pressure support (46%) [36] and NIOV
(by 245%) [33]. Notably, when the NIOV system was powered by compressed air rather than
oxygen, exercise endurance time was increased only by 13% [33]. The aforementioned ventilation
support strategies provide continuous unloading of the respiratory muscles and reduce the work of
breathing [11,26], and as such, are expected to yield greater improvement in exercise capacity compared
to the intermittent application of pNIV during recovery from exercise. This argument is further
supported by the absence of a reduction in ventilatory requirement or an increase in arterial oxygen
saturation during the successive bouts of high- or moderate-intensity exercise with the application of
pNIV compared to PLB in the present study (Table 3). Whilst intermittent use of pNIV offered less
improvement in exercise tolerance, it is more practical in typical PR settings and daily life. Studies in
the future may investigate the additive effect of oxygen supplementation to intermittent NIV support
during typical PR.
Our findings suggest that pNIV improved exercise tolerance compared to PLB not just by its direct
effect on respiratory mechanics (reducing DH), but also by partial alleviation of the associated adverse
hemodynamic responses. Use of pNIV resulted in an increase in cardiac output and systemic oxygen
delivery during exercise. This is most likely as a result of reduced DH and improved venous return,
which is in line with previously published reports following application of PAV [17] and administration
of bronchodilators or heliox [37,38]. This finding confirms that a common basis for enhanced exercise
performance in COPD may be associated with improved peripheral muscle oxygen availability and
reduced symptoms of leg discomfort afforded by interventions targeting the abnormal respiratory
mechanics in COPD.
VitaBreath provides positive inspiratory pressure support to reduce the work of breathing
and positive expiratory pressure to keep the airways open during expiration, thereby reducing air
trapping [12]. The mean increase in IC during the recovery periods compared to the end of exercise bouts
with pNIV (high-intensity: 140 mL; moderate-intensity: 170 mL) was within the clinically meaningful
margin for bronchodilator trials (138–175 mL) [39], most likely reflecting the improvement in expiratory
flow and thus lung emptying [7,39,40]. The increase in IC during recovery was matched by a significant
reduction in breathlessness that reached the minimal clinically important difference (1.0 unit) [7,40].
In contrast, PLB was not consistently associated with a clinically meaningful improvement in IC during
recovery; this is in keeping with previous work showing that exercise-induced DH normally persists for
several minutes following the end of exercise [41]. Furthermore, the mean reduction in breathlessness
scores during recovery from exercise did not reach the minimal clinically important difference [7,40].
We used two intermittent protocols with different duration and intensity characteristics to
explore the influence of intermittent pNIV on exercise tolerance in COPD patients with baseline and
exercise-induced dynamic hyperinflation. We expected that the use of pNIV during recovery following
successive 2-min exercise bouts at high-intensity would have conferred greater benefit being used
more frequently compared to 6-min bouts of moderate-intensity exercise. Our hypothesis was not
confirmed. The high-intensity protocol elicited greater exercise-induced DH compared to the moderate
intensity protocol (Table 3), hence the effectiveness of positive pressure ventilation on exercise tolerance,
physiological responses and symptoms is highly comparable between the two intermittent modalities.
Our findings suggest that pNIV could be applied in the PR setting to either prolong endurance at
a given training load sustained at moderate intensity and/or to allow greater training loads such as
the high-intensity protocol in the present study. Further research is required to confirm this as our
study provides evidence only during acute application of portable NIV; hence these data cannot be
extrapolated to give information about the effects during a long period of training.
All participants were given a device to use in daily life. Our data suggests that the VitaBreath device
improved anxiety around breathlessness, as well as perceived time of recovery from it. These findings
further support the clinically meaningful improvement of inspiratory capacity and breathlessness
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during recovery following the termination of high- and moderate-intensity exercise. Patients felt
benefits in speed, duration and confidence associated with their activities of daily living, which were
maintained at 3 months. The VitaBreath device does not change the underlying disease process
and, as expected, there was no change in frequency of breathlessness, nor the need to plan around,
or stop activities due to breathlessness. Patients describe the device as easy-to-use, but its portability
is unfavourable. However, it is important to note that over 95% of patients continue to use the
device regularly, and most would recommend it to another person with COPD. Despite these benefits,
few patients would purchase a device. This may, at least in part, reflect the UK National Health
Service, which provides treatment free at the point of delivery, and the socioeconomic status of this
patient group.
This is a single centre study and blinding the patients or investigators to the breathing modality was
not possible due to the lack of a sham pNIV device. Thus, the risk of a placebo effect cannot be excluded,
especially when considering the effect of the pNIV device on the reduction in breathlessness. We were
unable to measure the work of breathing directly during the recovery periods from exercise. This would
have allowed us to assess the effect of pNIV on respiratory muscle unloading. Use of optoelectronic
plethysmography would have allowed continuous assessment of end-expiratory volumes in the
transition from exercise to recovery [41]. Although most patients continued to use the device in daily
life, with no attrition in reported benefits over 12 weeks, these results may have been influenced by
study participation, including experience using the device under supervision during recovery from
moderate or intense exercise.
5. Conclusions
Use of pNIV during the recovery periods interspersing moderate or high intensity exercise
bouts enhances exercise tolerance compared to pursed lip breathing by lessening the symptoms of
breathlessness and by enhancing systemic oxygen availability. Future studies may investigate the
applicability and benefits of intermittent application of other available positive pressure ventilation
strategies during the recovery periods of high-intensity intermittent exercise in COPD.
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Appendix A : Methods
Appendix A.1 Study Population
Inclusion criteria:
1. Male or female aged 40 years or older.
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2. Current or previous smoking history: 10 or more pack years.
3. Spirometry confirmed stable COPD (GOLD stages II–IV) under optimal medical therapy.
4. Exhibit substantial exercise-induced DH (∆IC baseline > 0.15 L).
Exclusion criteria:
1. Orthopaedic, neurological or other concomitant diseases that significantly impair normal
biomechanical movement patterns, as judged by the investigator.
2. Moderate or severe COPD exacerbation within 6 weeks.
3. Unstable cardiac arrhythmia.
4. Unstable ischaemic heart disease, including myocardial infarction within 6 weeks.
5. Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy.
6. Uncontrolled hypertension.
7. Uncontrolled hypotension (systolic blood pressure (SBP) < 85 mmHg).
8. Uncontrolled diabetes.
9. Intolerance of the VitaBreath device.
Appendix A.2 Ramp Incremental Cardiopulmonary Exercise Testing (CPET)
All exercise tests were performed on an electromagnetically braked cycle ergometer (Ergoselect 200,
ergoline GmbH) with the patients maintaining a pedalling frequency of 50–60 rpm. The ramp
incremental cardiopulmonary exercise test consisted of a 3-min rest period, followed by 3-min
unloaded pedalling prior to ramp incremental loading, with increments of 5–10W. The following
pulmonary gas exchange and ventilatory variables were recorded breath-by-breath via a portable
gas exchange analyser (K4b2, Cosmed, Shepperton, UK) throughout the test: oxygen uptake (VO2),
carbon dioxide output (VCO2), respiratory exchange ratio (RER), minute ventilation (VE), tidal volume
(VT), and breathing frequency (bf). Arterial oxygen saturation and blood pressure was measured by
pulse oximetry (Nonin 8600; Nonin Medical, Plymouth, MN, USA) and a sphygmomanometer (MABIS
Healthcare PRECISION™), respectively. The modified Borg Scale was used to rate the magnitude of
dyspnoea and leg discomfort at the end of the test [16]. Inspiratory capacity (IC) manoeuvres were
performed at rest, every 2 min during cycling and at peak exercise, in order to evaluate the rate of
dynamic hyperinflation (DH) [9].
Appendix A.3 Central Hemodynamics
During both exercise protocols, patients were connected to a portable cardiographic conduction
device using impedance cardiography (Physio Flow, Enduro, PF-07, Manatec Biomedical, Folschviller,
France). The validity of this device has been certified in patients with COPD [18,21]. Cardiac Output
(CO), Heart Rate (HR) and Stroke Volume (SV) were recorded continuously at rest, during exercise
and in recovery by the Physio Flow device at 6s intervals as previously detailed [20]. Six electrodes
were placed in all subjects, two on the left carotid (Z1 and Z2), two in the breast area (EKG1 and
EKG2) and two in the chest area (Z3 and Z4-EKG3 (neutral)) [20]. From measurements of oxygen
uptake and cardiac output, whole body arteriovenous oxygen difference content was calculated using
the Fick equation [19]. Systemic oxygen delivery (DO2) was estimated by the following equation:
DO2 = Cardiac Output × Arterial Oxygen Content (CaO2est), L/min [17]. Arterial O2 content (CaO2)
was estimated as CaO2 (mL/100 mL) = 1.39× (Hb)× SpO2, where (Hb) is haemoglobin concentration [42].
Appendix A.4 Sample Size Justification
Verification of sample size within each exercise modality was based on the study by Bianchi
and colleagues comparing pressure support ventilation (PSV) to control breathing during exercise.
Using the mean difference in endurance time (3.4 min) between PSV and control breathing, and SD
(4.6 min), an alpha significance level of 0.05 (2-sided) and 90% power, a minimum total sample size of
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10 patients was calculated to be sufficient to detect significant differences in endurance time between
pNIV and PLB trials within each exercise modality [22,43]. To compensate for possible dropouts
(i.e., 20%), a total sample size of 24 patients was recruited. Randomisation was performed at the study
outset using stratified randomisation to balance the two groups in terms of baseline lung function
(FEV1% predicted) and peak exercise capacity (WRpeak).
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